E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with T
>
Issuers starting with T, CV only
>
All stories on Travere Therapeutics Inc.
>
Stories on Travere Therapeutics Inc., CV only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Travere Therapeutics Inc.
10/10/2024
CV
Market Commentary:
Ares convertible preferreds hold gains; Snowflake improves; Travere uptrend continues
9/6/2024
CV
Market Commentary:
Varonis Systems convertibles expand on debut; Travere Therapeutics jumps; Jazz lower
9/21/2023
CV
Market Commentary:
Splunk convertibles in focus on buyout by Cisco Systems; NIO comes in; Travere plunges
3/25/2022
CV
Market Commentary:
Ascendis convertibles gain, Blackstone drops in secondary debut; EQT shoots higher
3/25/2022
CV
Market Commentary:
Morning Commentary: Ascendis convertibles gain, Blackstone drops in secondary debut
3/11/2022
CV
Travere greenshoe lifts 2.25% convertible notes to $316.25 million
3/10/2022
CV
Market Commentary:
Travere Therapeutics convertibles tick higher; China-based issuers under pressure
3/10/2022
CV
Market Commentary:
Morning Commentary: Travere Therapeutics convertibles tick higher; Pinduoduo active
3/9/2022
CV
Market Commentary:
Travere Therapeutics convertibles jump on debut; MongoDB expands; Snap notes rebound
3/9/2022
CV
Market Commentary:
Morning Commentary: Travere Therapeutics convertibles price, jump on aftermarket debut
3/8/2022
CV
New Issue: Travere Therapeutics sells upsized $275 million 2.25% seven-year convertibles, up 35%
3/8/2022
CV
Market Commentary:
Travere Therapeutics eyed; Southwest, American Airlines improve; Mandiant notes active
3/8/2022
CV
Market Commentary:
Morning Commentary: Travere Therapeutics convertibles offering eyed amid volatile market
3/8/2022
CV
Travere Therapeutics talks $250 million seven-year convertibles at 1.75%-2.25%, up 32.5%-37.5%
2/2/2021
CV
Market Commentary:
Mitek Systems convertible offering eyed; Travere notes active; BridgeBio rebounds
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
